Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | 65.91% | 7.42% | -- | -124.85% |
| Total Depreciation and Amortization | -- | 4.55% | 5.61% | -- | -78.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -112.48% | -84.47% | -- | 151.49% |
| Change in Net Operating Assets | -- | -98.51% | -262.07% | -- | -65.13% |
| Cash from Operations | -- | -678.33% | -8,849.47% | -- | 25.18% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -5,184.13% | -186.83% | -- | -767.06% |
| Cash from Investing | -- | -5,184.13% | -186.83% | -- | 89.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -28.94% | -41.23% | -- | 95.26% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -115.54% | 94.32% | -- | -25.97% |
| Foreign Exchange rate Adjustments | -- | -89.79% | -145.74% | -- | -102.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -2,440.59% | -144.76% | -- | 101.59% |